145 related articles for article (PubMed ID: 37290280)
1. Potential direct role of synuclein in dopamine transport and its implications for Parkinson's disease pathogenesis.
Kim M; Bezprozvanny I
Biochem Biophys Res Commun; 2023 Sep; 671():18-25. PubMed ID: 37290280
[TBL] [Abstract][Full Text] [Related]
2. Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
Lima VA; do Nascimento LA; Eliezer D; Follmer C
ACS Chem Neurosci; 2019 Jan; 10(1):690-703. PubMed ID: 30352158
[TBL] [Abstract][Full Text] [Related]
3. Rab11 modulates α-synuclein-mediated defects in synaptic transmission and behaviour.
Breda C; Nugent ML; Estranero JG; Kyriacou CP; Outeiro TF; Steinert JR; Giorgini F
Hum Mol Genet; 2015 Feb; 24(4):1077-91. PubMed ID: 25305083
[TBL] [Abstract][Full Text] [Related]
4. Different Effects of α-Synuclein Mutants on Lipid Binding and Aggregation Detected by Single Molecule Fluorescence Spectroscopy and ThT Fluorescence-Based Measurements.
Ruf VC; Nübling GS; Willikens S; Shi S; Schmidt F; Levin J; Bötzel K; Kamp F; Giese A
ACS Chem Neurosci; 2019 Mar; 10(3):1649-1659. PubMed ID: 30605594
[TBL] [Abstract][Full Text] [Related]
5. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
[TBL] [Abstract][Full Text] [Related]
6. Posttranslational modification and mutation of histidine 50 trigger alpha synuclein aggregation and toxicity.
Xiang W; Menges S; Schlachetzki JC; Meixner H; Hoffmann AC; Schlötzer-Schrehardt U; Becker CM; Winkler J; Klucken J
Mol Neurodegener; 2015 Mar; 10():8. PubMed ID: 25886189
[TBL] [Abstract][Full Text] [Related]
7. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation.
Lázaro DF; Rodrigues EF; Langohr R; Shahpasandzadeh H; Ribeiro T; Guerreiro P; Gerhardt E; Kröhnert K; Klucken J; Pereira MD; Popova B; Kruse N; Mollenhauer B; Rizzoli SO; Braus GH; Danzer KM; Outeiro TF
PLoS Genet; 2014 Nov; 10(11):e1004741. PubMed ID: 25393002
[TBL] [Abstract][Full Text] [Related]
8. Fibrillation of α-synuclein triggered by bacterial endotoxin and lipid vesicles is modulated by N-terminal acetylation and familial Parkinson's disease mutations.
Monteiro Neto JR; Lima VA; Follmer C
FEBS J; 2024 Mar; 291(6):1151-1167. PubMed ID: 38069536
[TBL] [Abstract][Full Text] [Related]
9. Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.
Butkovich LM; Houser MC; Chalermpalanupap T; Porter-Stransky KA; Iannitelli AF; Boles JS; Lloyd GM; Coomes AS; Eidson LN; De Sousa Rodrigues ME; Oliver DL; Kelly SD; Chang J; Bengoa-Vergniory N; Wade-Martins R; Giasson BI; Joers V; Weinshenker D; Tansey MG
J Neurosci; 2020 Sep; 40(39):7559-7576. PubMed ID: 32868457
[TBL] [Abstract][Full Text] [Related]
10. Alpha synuclein dimers and oligomers are increased in overexpressing conditions in vitro and in vivo.
Marmolino D; Foerch P; Atienzar FA; Staelens L; Michel A; Scheller D
Mol Cell Neurosci; 2016 Mar; 71():92-101. PubMed ID: 26711807
[TBL] [Abstract][Full Text] [Related]
11. In silico analysis of alpha-synuclein protein variants and posttranslational modifications related to Parkinson's disease.
da Silva ANR; Pereira GRC; Bonet LFS; Outeiro TF; De Mesquita JF
J Cell Biochem; 2024 Mar; 125(3):e30523. PubMed ID: 38239037
[TBL] [Abstract][Full Text] [Related]
12. Comparison of motor performance, brain biochemistry and histology of two A30P α-synuclein transgenic mouse strains.
Piltonen M; Savolainen M; Patrikainen S; Baekelandt V; Myöhänen TT; Männistö PT
Neuroscience; 2013 Feb; 231():157-68. PubMed ID: 23219665
[TBL] [Abstract][Full Text] [Related]
13. Synaptic dysfunction in Parkinson's disease.
Picconi B; Piccoli G; Calabresi P
Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
[TBL] [Abstract][Full Text] [Related]
14. Endosulfine-alpha inhibits membrane-induced α-synuclein aggregation and protects against α-synuclein neurotoxicity.
Ysselstein D; Dehay B; Costantino IM; McCabe GP; Frosch MP; George JM; Bezard E; Rochet JC
Acta Neuropathol Commun; 2017 Jan; 5(1):3. PubMed ID: 28069058
[TBL] [Abstract][Full Text] [Related]
15. N-terminal acetylation mutants affect alpha-synuclein stability, protein levels and neuronal toxicity.
Vinueza-Gavilanes R; Íñigo-Marco I; Larrea L; Lasa M; Carte B; Santamaría E; Fernández-Irigoyen J; Bugallo R; Aragón T; Aldabe R; Arrasate M
Neurobiol Dis; 2020 Apr; 137():104781. PubMed ID: 31991248
[TBL] [Abstract][Full Text] [Related]
16. Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinson´s disease.
Kilpeläinen T; Julku UH; Svarcbahs R; Myöhänen TT
Sci Rep; 2019 Nov; 9(1):17382. PubMed ID: 31758049
[TBL] [Abstract][Full Text] [Related]
17. Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies.
Schildknecht S; Gerding HR; Karreman C; Drescher M; Lashuel HA; Outeiro TF; Di Monte DA; Leist M
J Neurochem; 2013 May; 125(4):491-511. PubMed ID: 23452040
[TBL] [Abstract][Full Text] [Related]
18. The proSAAS Chaperone Provides Neuroprotection and Attenuates Transsynaptic α-Synuclein Spread in Rodent Models of Parkinson's Disease.
Lindberg I; Shu Z; Lam H; Helwig M; Yucer N; Laperle A; Svendsen CN; Di Monte DA; Maidment NT
J Parkinsons Dis; 2022; 12(5):1463-1478. PubMed ID: 35527562
[TBL] [Abstract][Full Text] [Related]
19. A53T Mutant Alpha-Synuclein Induces Tau-Dependent Postsynaptic Impairment Independently of Neurodegenerative Changes.
Teravskis PJ; Covelo A; Miller EC; Singh B; Martell-Martínez HA; Benneyworth MA; Gallardo C; Oxnard BR; Araque A; Lee MK; Liao D
J Neurosci; 2018 Nov; 38(45):9754-9767. PubMed ID: 30249789
[TBL] [Abstract][Full Text] [Related]
20. GBA haploinsufficiency accelerates alpha-synuclein pathology with altered lipid metabolism in a prodromal model of Parkinson's disease.
Ikuno M; Yamakado H; Akiyama H; Parajuli LK; Taguchi K; Hara J; Uemura N; Hatanaka Y; Higaki K; Ohno K; Tanaka M; Koike M; Hirabayashi Y; Takahashi R
Hum Mol Genet; 2019 Jun; 28(11):1894-1904. PubMed ID: 30689867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
